Crunching the numbers. Responsibly.
BACKGROUND: Berotralstat (BCX7353) is an oral, once-daily inhibitor of plasma kallikrein in development for the prophylaxis of hereditary angioedema (HAE) attacks. OBJECTIVE: Our aim was to determine the efficacy, safety, and tolerability of berotralstat in patients with HAE over a 24-week treatment period (the phase 3 APeX-2 trial). METHODS: APeX-2 was a double-blind, parallel-group study that randomized patients at 40 sites in 11 countries 1:1:1 to receive once-daily berotralstat in a dose of 110 mg or 150 mg or placebo (Clinicaltrials.gov identifier NCT03485911). Patients aged 12 years or older with HAE due to C1 inhibitor deficiency and at least 2 investigator-confirmed HAE attacks in the first 56 days of a prospective run-in period were eligible. The primary efficacy end point was the rate of investigator-confirmed HAE attacks during the 24-week treatment period. RESULTS: A total of 121 patients were randomized; 120 of them received at least 1 dose of the study drug (n = 41, 40, and 39 in the 110-mg dose of berotralstat, 150-mg of dose berotralstat, and placebo groups, respectively). Berotralstat demonstrated a significant reduction in attack rate at both 110 mg (1.65 attacks per month; P = .024) and 150 mg (1.31 attacks per month; P < .001) relative to placebo (2.35 attacks per month). The most frequent treatment-emergent adverse events that occurred more with berotralstat than with placebo were abdominal pain, vomiting, diarrhea, and back pain. No drug-related serious treatment-emergent adverse events occurred. CONCLUSION: Both the 110-mg and 150-mg doses of berotralstat reduced HAE attack rates compared with placebo and were safe and generally well tolerated. The most favorable benefit-to-risk profile was observed at a dose of 150 mg per day.
Berotralstat demonstrated a significant reduction in attack rate at both 110 mg (1.65 attacks per month; P = .024) and 150 mg (1.31 attacks per month; P < .001) relative to placebo (2.35 attacks per month).
prespecified ITT primary analysis with consistent estimates, confidence intervals, and sensitivity analyses
No drug-related serious treatment-emergent adverse events occurred.
systematic blinded harms assessment directly supports this trial-bounded safety statement
The most favorable benefit-to-risk profile was observed at a dose of 150 mg per day.
greater efficacy with similar short-term tolerability, tempered by small groups and 24-week exposure
Derived from the full evaluation — not a separate score.
Strengths
Treatment allocation was generated in SAS, implemented through an interactive web-response system, and concealed from patients, investigators, and most study personnel. The primary endpoint was analyzed in the ITT population with an appropriate count model and duration offset.
↳ Methods, Study design and Statistical analyses, pp. 165–167
The trial tests a once-daily oral prophylactic against placebo after describing available mechanism-based alternatives as requiring parenteral administration. This directly addresses a documented treatment preference among patients with HAE.
↳ Introduction, pp. 165–166; Discussion, p. 171
The Hochberg hierarchy is described prospectively, and subsequent results are explicitly labelled nominal after formal testing stopped. Table III reports serious events, severe events, treatment discontinuations, and common adverse events by arm.
↳ Methods, Statistical analyses, pp. 166–167; Results, pp. 167–169; Table III, p. 171
Limitations
The randomized treatment period lasted 24 weeks, limiting conclusions about long-term durability and safety for a lifelong disorder. The Discussion acknowledges that longer-term studies remain necessary.
↳ Discussion, p. 171
Treatment groups contained only 40–41 randomized patients, and 93–95% of participants were White. This restricts subgroup analysis and confidence in transfer beyond the represented population.
↳ Table I, p. 168; Discussion, p. 171
The Results state that two patients withdrew consent but then assign one such withdrawal to the 150-mg arm and two to placebo. The discrepancy is peripheral to the ITT efficacy estimates but reduces reporting precision.
↳ Results, Study population and treatment compliance, p. 167
The primary attack-rate result rests on a prespecified, randomized ITT analysis with concealed allocation, broad blinding, and sensitivity analyses that supported the main model. Statistical reporting is disciplined: the nonsignificant AE-QoL comparison is disclosed, and later secondary analyses are labelled nominal after hierarchical testing stopped. The 150-mg benefit-risk conclusion is reasonable within the trial, but small treatment groups and 24-week exposure limit long-term certainty. Contextual scoring also reflects the tension between the broad “any patient” statement and the paper's subsequent acknowledgment that it cannot guide patient selection.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Strong4.2
Confidence highThe trial provides confirmatory phase 3 evidence for an oral once-daily prophylactic option where the established mechanism-based alternatives described were parenteral. The advance is clinically meaningful but remains bounded by the enrolled population and 24-week evaluation.
“all require parenteral administration”
The study used centrally implemented stratified randomization, broad blinding, ITT efficacy analysis, an appropriate negative-binomial model, hierarchical multiplicity control, and systematic harms assessment. Small treatment groups and short exposure limit precision and long-term safety characterization rather than the validity of the primary analysis.
“Primary and secondary efficacy analyses were conducted by using the intent-to-treat population.”
The primary result, nonsignificant AE-QoL comparison, and nominal analyses after the hierarchy stopped are explicitly distinguished. Some discussion language about attack severity and the treatment's clinical importance is more promotional than the confirmatory evidence warrants, but it does not alter the central conclusion.
“nominal analyses are reported for clarity”
The paper situates berotralstat against androgens and existing parenteral mechanism-based therapies and acknowledges short duration, small groups, and absent patient-selection guidance. The claim that treatment could suit any patient is broader than the ad hoc predictor analysis, although the following limitations paragraph tempers it.
“The results from this trial do not provide guidance for the selection of patients”
Lower confidence on Positioning — domain match limited.
Caveats4 of 4 checks
The primary efficacy and safety figures reconcile, but the narrative accounting of consent withdrawals contains a minor arithmetic inconsistency. A separate discussion inference about reduced attack severity is exploratory and appropriately hedged, though not based on a formal contrast.
Prospective registration, ethics review, consent, independent safety monitoring, funding, and extensive conflicts of interest are declared. No supplied-text discrepancy in registration or availability reporting was demonstrated.
Flags: 3 declared / 5 total
18 of 19 checkable references verified
20 references in manuscript 1 are books, websites or datasets — counted, but not index-checkable
No retraction notice found in Retraction Watch.
Sources: Retraction Watch ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
A multicountry phase 3 placebo-controlled trial of a practical once-daily regimen places the findings close to operational treatment decisions. The 24-week treatment period leaves additional evidence needed for durable long-term implementation.
“a 24-week, double-blind evaluation”
AI-generated, human-governed. Something look off? Contact us to request a review.